Spotlight on pomalidomide: could less be more?

Por Zander, T, Aebi, S, Pabst, T, Renner, C, Driessen, C
Publicado no Leukemia (2017)

Zinc regulates cytokine induction by superantigens and lipopolysaccharide.

Por Driessen, C, Hirv, K, Kirchner, H, Rink, L
Publicado em 1995

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance

Por Kraus, M, Bader, J, Overkleeft, H, Driessen, C
Publicado em 2013

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

Por Besse, L, Kraus, M, Besse, A, Bader, J, Silzle, T, Mehrling, T, Driessen, C
Publicado no Blood Cancer J (2017)

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: The introduction of a new measure

Por Driessen, C. M. L., de Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., Vreugdenhil, G.
Publicado em 2011

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado no Leukemia (2018)

Splenic size after division of the short gastric vessels in Nissen fundoplication in children

Por Driessen, C., Paulus, G. F., Robben, S. G., Tjon a Ten, W. E., Van den Neucker, A., Verhoeven, B. H., Van Heurn, L. W. E.
Publicado em 2011

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

Por Soriano, G P, Besse, L, Li, N, Kraus, M, Besse, A, Meeuwenoord, N, Bader, J, Everts, B, den Dulk, H, Overkleeft, H S, Florea, B I, Driessen, C
Publicado no Leukemia (2016)